Biotech | January 18, 2022
DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
He has over 22 years of experience in pharmaceutical sales & business development
Effectiveness of Covaxin against the Omicron variant is currently being studied
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Acute therapies continue to report strong growth compared to chronic ones.
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
